# Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas

> **NCT02776163** · PHASE2 · COMPLETED · sponsor: **Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University** · enrollment: 107 (actual)

## Conditions studied

- Salivary Gland Tumors
- Head and Neck Cancer

## Interventions

- **DRUG:** Nedaplatin
- **DRUG:** Docetaxel
- **RADIATION:** Intensity-modulated radiotherapy

## Key facts

- **NCT ID:** NCT02776163
- **Lead sponsor:** Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-01
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-12-31
- **Target enrollment:** 107 (ACTUAL)
- **Last updated:** 2024-07-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02776163

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02776163, "Postoperative Concurrent Chemoradiotherapy in Treating Patients With High-Risk Salivary Gland Carcinomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02776163. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*